Izalontamab Brengitecan (Iza-bren) in Locally Advanced or Metastatic Non‑Small Cell Lung Cancer With Actionable Genomic Alterations Outside Classical EGFR Mutations: A Phase Ib Study
Iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse genomic alterations (GAs) outside classical EGFR mutations, especially in EGFR exon20 insertions/non‑classical mutations and HER2 mutations.
To evaluate the safety and efficacy of izalontamab brengitecan (iza‑bren) in patients with non‑small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor (EGFR) mutations.
Izalontamab brengitecan is a bispecific antibody‑drug conjugate targeting EGFR and HER3, showing promising activity across EGFR exon20 insertions and HER2 mutations, thereby addressing unmet needs in NSCLC subgroups lacking effective targeted therapies.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT